Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised…

Overview of attention for article published in The Lancet, November 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 18 news outlets
blogs: 5 blogs
twitter: 88 X users

reddit: 1 Redditor
guideline: 2 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 61 Mendeley

So far, Altmetric has seen 96 X posts from 88 X users, with an upper bound of 204,174 followers.

RT @SU2Cscience: Yvonne Mowrey and David Kirsch of the @SU2C-@Merck Catalyst® Research Team published in @TheLancet showing the addition of…

Adding pembrolizumab to preoperative treatment significantly increases disease-free survival in stage III soft tissue sarcoma patients. by Mowery YM, Ballman KV (...) Kirsch DG et 25 al. in Lancet https://t.co/GUHzoQBtLj #MedX #MedResearch

RT @DKirschMDPhD: Just in time for #CTOS2024: Thrilled to share SU2C-SARC032 (NCT03092323), a randomized trial of pembrolizumab in Stage 3…

Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial - The Lancet https://t.co/4it6LH3VZG

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 92 additional X posts.